Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Inotek Pharma (ITEK)

Inotek Pharma (ITEK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 82,749
  • Shares Outstanding, K 27,220
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,850 K
  • 60-Month Beta 3.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.62
Trade ITEK with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.64
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 01/03/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/17
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.48
  • Growth Rate Est. (year over year) +208,225.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.96 +55.10%
on 12/06/17
3.25 -6.46%
on 01/04/18
+0.76 (+33.33%)
since 12/04/17
3-Month
1.96 +55.10%
on 12/06/17
3.80 -20.00%
on 10/13/17
+1.00 (+49.02%)
since 10/04/17
52-Week
0.85 +257.65%
on 07/10/17
3.80 -20.00%
on 10/13/17
+1.24 (+68.89%)
since 01/04/17

Most Recent Stories

More News
Global Glaucoma Therapeutics Market Size Worth USD 11.05 Billion at 6.1% CAGR; Improved Distribution Network of Key Companies to Aid Growth: Fortune Business Insights(TM)

According to the report, Glaucoma Therapeutics market size is projected reach USD 7.34 billion by 2026. Global Glaucoma Therapeutics market was USD 6.59 billion in 2018 and is anticipated to exhibit a...

ABBV : 106.70 (+0.99%)
AERI : 18.75 (-2.60%)
AGN : 193.02 (+0.02%)
ITEK : 3.04 (-5.00%)
NVS : 84.01 (+0.61%)
PFE : 34.39 (+0.56%)
Glaucoma Therapeutics Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027

The Global is estimated to value over USD 10.1 billion by 2027 end with a CAGR of over 6% during the forecast period 2020 to 2027.

AERI : 18.75 (-2.60%)
AGN : 193.02 (+0.02%)
ITEK : 3.04 (-5.00%)
NVS : 84.01 (+0.61%)
PFE : 34.39 (+0.56%)
SNPHF : 13.6000 (-3.55%)
TEVA : 10.52 (-0.57%)
VRX.TO : 30.80 (-3.33%)
Glaucoma Drugs Market Size | Global Industry Analysis and Opportunity Assessment 2021-2027

The latest research report on delivers a comprehensive study on current market trends. The outcome also includes revenue forecasts, statistics, market valuations which illustrate its growth trends and...

AERI : 18.75 (-2.60%)
AGN : 193.02 (+0.02%)
ITEK : 3.04 (-5.00%)
MRK : 73.13 (+1.33%)
NMUS : 0.6500 (-9.52%)
NVS : 84.01 (+0.61%)
OCAT : 8.47 (+0.12%)
OCUL : 18.51 (+6.81%)
OHRP : 5.39 (+30.19%)
PRGO : 41.04 (+1.16%)
PFE : 34.39 (+0.56%)
SNPHF : 13.6000 (-3.55%)
SCMP : 18.05 (+0.28%)
TEVA : 10.52 (-0.57%)
VRX.TO : 30.80 (-3.33%)
US Glaucoma Drugs Market Size 2021 By Trends Evaluation, Business Opportunities, Consumption, Growth Rate, Top Manufacturer, New Project Investment, Regional Analysis and Forecast to 2027

AI Market Report is working on a new report title Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027? Rise in prevalence of eye disorders such as Presbyopia, Macular Degeneration...

AGN : 193.02 (+0.02%)
ITEK : 3.04 (-5.00%)
MRK : 73.13 (+1.33%)
NMUS : 0.6500 (-9.52%)
NVS : 84.01 (+0.61%)
OCAT : 8.47 (+0.12%)
OCUL : 18.51 (+6.81%)
OHRP : 5.39 (+30.19%)
PRGO : 41.04 (+1.16%)
PFE : 34.39 (+0.56%)
SNPHF : 13.6000 (-3.55%)
SCMP : 18.05 (+0.28%)
TEVA : 10.52 (-0.57%)
VRX.TO : 30.80 (-3.33%)
Outlook on the Glaucoma Therapeutics Global Market to 2025 - Impact of COVID-19

, /PRNewswire/ -- The report has been added to offering.

AERI : 18.75 (-2.60%)
AGN : 193.02 (+0.02%)
ITEK : 3.04 (-5.00%)
MRK : 73.13 (+1.33%)
NVS : 84.01 (+0.61%)
PFE : 34.39 (+0.56%)
SNPHF : 13.6000 (-3.55%)
Educative: Can Businesses recover from COVID-19 impact in Glaucoma Drugs Market

A recent report on provides a detailed analysis on the industry size, revenue forecasts and geographical landscape pertaining to this business space. Additionally, the report highlights primary obstacles...

AERI : 18.75 (-2.60%)
AGN : 193.02 (+0.02%)
ITEK : 3.04 (-5.00%)
MRK : 73.13 (+1.33%)
NMUS : 0.6500 (-9.52%)
NVS : 84.01 (+0.61%)
OCAT : 8.47 (+0.12%)
OCUL : 18.51 (+6.81%)
OHRP : 5.39 (+30.19%)
PRGO : 41.04 (+1.16%)
PFE : 34.39 (+0.56%)
SNPHF : 13.6000 (-3.55%)
SCMP : 18.05 (+0.28%)
TEVA : 10.52 (-0.57%)
VRX.TO : 30.80 (-3.33%)
Glaucoma Therapeutics Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027

The Global is estimated to value over USD 10.1 billion by 2027 end with a CAGR of over 6% during the forecast period 2020 to 2027.

AERI : 18.75 (-2.60%)
AGN : 193.02 (+0.02%)
ITEK : 3.04 (-5.00%)
NVS : 84.01 (+0.61%)
PFE : 34.39 (+0.56%)
SNPHF : 13.6000 (-3.55%)
TEVA : 10.52 (-0.57%)
VRX.TO : 30.80 (-3.33%)
Glaucoma Therapeutics Market to Reach USD 11.05 Billion at 6.1% CAGR by 2027; Rising Research on Prostaglandin Analogs, says Fortune Business Insights(TM)

The global glaucoma therapeutics market is set to gain impetus from the increasing research activities on prostaglandin analogs. It is further creating a surging shift of patients towards this drug class....

AERI : 18.75 (-2.60%)
AGN : 193.02 (+0.02%)
ITEK : 3.04 (-5.00%)
NVS : 84.01 (+0.61%)
Glaucoma Therapeutics Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027

The Global is estimated to value over USD 10.1 billion by 2027 end with a CAGR of over 6% during the forecast period 2020 to 2027.

AERI : 18.75 (-2.60%)
AGN : 193.02 (+0.02%)
ITEK : 3.04 (-5.00%)
NVS : 84.01 (+0.61%)
PFE : 34.39 (+0.56%)
SNPHF : 13.6000 (-3.55%)
TEVA : 10.52 (-0.57%)
VRX.TO : 30.80 (-3.33%)
Glaucoma Drugs Market Opportunities, Demands and Growth Revenue by 2025 | Brandessence Market Research Report

AERI : 18.75 (-2.60%)
AGN : 193.02 (+0.02%)
CANF : 1.8400 (+2.22%)
ITEK : 3.04 (-5.00%)
MRK : 73.13 (+1.33%)
NMUS : 0.6500 (-9.52%)
NVS : 84.01 (+0.61%)
OCAT : 8.47 (+0.12%)
OCUL : 18.51 (+6.81%)
OHRP : 5.39 (+30.19%)
PRGO : 41.04 (+1.16%)
PFE : 34.39 (+0.56%)
SNPHF : 13.6000 (-3.55%)
SCMP : 18.05 (+0.28%)
TEVA : 10.52 (-0.57%)
VRX.TO : 30.80 (-3.33%)

Business Summary

Inotek Pharmaceuticals Corporation is a biopharmaceutical company. The company is focused on the discovery, development and commercialization of novel therapies to treat glaucoma and diseases of the eye. Inotek Pharmaceuticals Corporation is headquartered in Lexington, Massachusetts.

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 3.38
1st Resistance Point 3.21
Last Price 3.04
1st Support Level 2.91
2nd Support Level 2.78
3rd Support Level N/A

See More

52-Week High 3.80
Last Price 3.04
Fibonacci 61.8% 2.67
Fibonacci 50% 2.33
Fibonacci 38.2% 1.98
52-Week Low 0.85

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar